The introduction of blood biomarkers for Alzheimer’s disease is revolutionizing the biological diagnosis of this disease, enabling faster diagnosis i1
The treatments available for Alzheimer’s disease are most effective in the early stages, when it is still asymptomatic. That is why an early diagnosi1
The Neurocloud platform, developed by Qubiotech, optimizes the diagnosis and monitoring of conditions such as Alzheimer’s disease, epilepsy and multi1
Researchers at the Clínic-IDIBAPS have created a tool that allows for the quantification of brain asymmetry in patients with frontotemporal dementia,1
Numerous scientific studies have identified preventable potential risk factors for the development of dementia. Fourteen of these factors and their i1
HUB Alzheimer Barcelona is a pioneering collaborative initiative rooted in a commitment to transform the future of research and provide support for p1
These findings offer a solid basis for designing clinical trials of therapies aimed at modifying the development of these neurodegenerative diseases1
The study analysed head impacts among professional footballers in World Cup matches over a period of 50 years, and observed a significant number of t1
The study aims to better understand the biological processes that are altered differently in men and women in the early stages of Alzheimer's disease1
Researchers at the Clínic-IDIBAPS led a study published in the Alzheimer’s & Dementia journal on the relationship between the integrity of the locus1
